Orion OyjORINF +4.81%100 Altman Z-Score is 9.15 as of Jun. 26, 2026, which is 11% below its 10-year median of 10.33. GuruFocus rates ORINF with a GF Score™ of 100/100 and a GF Value™ of $86.78. The stock has 2 warning signs investors should review. Among 952 Drug Manufacturers companies, Orion Oyj ranks better than 83.82% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 8.94 is strong.
Orion Oyj has a Altman Z-Score of 9.15, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Orion Oyj's Altman Z-Score or its related term are showing as below:
ORINF'
s Altman Z-Score Range Over the Past 10 Years
Min: 6.24 Med: 10.33 Max: 16.69
Current: 8.94
During the past 13 years, Orion Oyj's highest Altman Z-Score was 16.69. The lowest was 6.24. And the median was 10.33.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Orion Oyj Altman Z-Score Related Terms
Orion Oyj Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Orion Oyj's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORINF vs LLY, JNJ, ABBV: Altman Z-Score Comparison
For the Drug Manufacturers - General subindustry, Orion Oyj's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj Altman Z-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Orion Oyj's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Orion Oyj's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.2946
+
1.4
*
0.4914
+
3.3
*
0.3243
+
0.6
*
10.1568
+
1.0
*
0.9462
=
9.15
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Orion Oyj (ORINF) has a Altman Z-Score of 9.15 as of Jun. 26, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Orion Oyj and its competitors. This is 11% below median its historical median of 10.33. Over the past decade, Orion Oyj's Altman Z-Score has ranged from 6.24 to 16.69. According to the industry distribution chart, Orion Oyj ranks #154 out of 952 companies in the Drug Manufacturers industry, placing it in the top 16.2%.
Is Orion Oyj's Altman Z-Score too high?
Orion Oyj's current Altman Z-Score of 9.15 is 11% below median its 10-year median of 10.33. Over the past 10 years, this metric has ranged from a low of 6.24 to a high of 16.69. The Drug Manufacturers industry median Altman Z-Score is 3.30. Orion Oyj's value of 9.15 is 177.7% above this industry median. Based on the distribution chart, Orion Oyj ranks #154 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orion Oyj has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's Altman Z-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #154 out of 952 companies for Altman Z-Score. This places Orion Oyj in the top 16% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.30. Orion Oyj's value of 9.15 is 177.7% above this benchmark. Historically, Orion Oyj's own Altman Z-Score has ranged from 6.24 to 16.69 over the past decade. While the company's 10-year median is 10.33 vs. the industry median of 3.30, Orion Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Oyj's current Altman Z-Score of 9.15 is 177.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Orion Oyj and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Oyj's current Altman Z-Score is 9.15, which is 11% below median its own 10-year median of 10.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Orion Oyj (ORINF) has a current Altman Z-Score of 9.15. The stock's GF Value™ is $86.78, compared to a current price of $82.75 — trading 4.6% below its estimated fair value. The current Altman Z-Score is 9.15, which is 11% below median its 10-year median of 10.33 and 177.7% above the Drug Manufacturers industry median of 3.30. Orion Oyj's overall GF Score™ is 100/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Orion Oyj (ORINF), the current Altman Z-Score is 9.15 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (ORINF) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be undervalued.
The current stock price of $82.75 is trading 4.6% below its estimated GF Value™ of $86.78.
Key valuation signals for ORINF:
Altman Z-Score: 9.15 (11% below median its 10-year median of 10.33)
GF Value™: $86.78 vs. price of $82.75 (4.6% below fair value)
Industry Position: 177.7% above the Drug Manufacturers median (#154 of 952)
No single metric tells the full story. See the ORINF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
100GF Score
Get the complete analysis for ORINF
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORINF has been successfully added to your 
